PMID- 35264973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of 
      Lung Adenocarcinoma.
PG  - 857289
LID - 10.3389/fphar.2022.857289 [doi]
LID - 857289
AB  - Tumor microenvironment plays an important role in the development, progression, 
      and prognosis of lung adenocarcinoma. Exploring new biomarkers based on the 
      immune microenvironment of lung adenocarcinoma can effectively predict the 
      prognosis and provide effective clinical treatment. In this study, we used the 
      ESTIMATE algorithm to score the immune and stromal components in lung 
      adenocarcinoma data downloaded from the TCGA database. The result showed that the 
      immune/stromal score was associated with clinical features and prognosis of lung 
      adenocarcinoma patients. Interleukin-7 receptor (IL7R) is an important prognostic 
      biomarker identified by intersection analysis of protein-protein interaction 
      networks and Cox regression survival analysis. According to TCGA and Oncomine 
      database analysis, IL7R expression in adenocarcinoma tissues was significantly 
      lower than that in normal lung tissues and was further verified in clinical 
      tissue samples. Survival analysis showed IL7R was an independent prognostic 
      factor of lung adenocarcinoma. IL7R expression was positively correlated with the 
      overall survival and progression-free survival of lung adenocarcinoma patients 
      and negatively correlated with tumor size. Our results suggest that IL7R inhibits 
      tumor growth by regulating the proportion of immune infiltrating cells in the 
      tumor immune microenvironment. IL7R could be a beneficial prognostic marker in 
      patients with lung adenocarcinoma and has great potential in immune therapy.
CI  - Copyright (c) 2022 Wang, Chang, Wang, Wu, Huang, Sun, Liu, Yu and Mao.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Chang, Shujian
AU  - Chang S
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Wang, Teng
AU  - Wang T
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Wu, Ruirong
AU  - Wu R
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Huang, Zebo
AU  - Huang Z
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Sun, Junjie
AU  - Sun J
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Liu, Jingjing
AU  - Liu J
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
FAU - Yu, Yan
AU  - Yu Y
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital, 
      Harbin, China.
FAU - Mao, Yong
AU  - Mao Y
AD  - Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220221
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8899515
OTO - NOTNLM
OT  - IL7R
OT  - lung adenocarcinoma
OT  - prognosis
OT  - tumor immunological microenvironment
OT  - tumor infiltrating lymphocytes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/11 06:00
MHDA- 2022/03/11 06:01
PMCR- 2022/02/21
CRDT- 2022/03/10 05:44
PHST- 2022/01/18 00:00 [received]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/03/10 05:44 [entrez]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/03/11 06:01 [medline]
PHST- 2022/02/21 00:00 [pmc-release]
AID - 857289 [pii]
AID - 10.3389/fphar.2022.857289 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Feb 21;13:857289. doi: 10.3389/fphar.2022.857289. 
      eCollection 2022.